MEN1 and acute myeloid leukemia: After years of optimization and drug selection, four drugs that inhibit MLL-menin binding have recently entered clinical testing as single agents for AML (K0539 (NCT04067336); SNDX-5613 (NCT04065399); JNJ-75276617 (NCT04811560); DS-1594b (NCT04752163); BMF-219 (NCT05153330).